Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Biogen
Company Monitoring Page for Biogen
latest headlines for company on cafepharma
FDA Approves Biogen, Sage’s Zurzuvae as First Pill for Postpartum Depression
BioSpace
Sun, 08/6/23 - 09:39 pm
Tags:
Biogen
,
SAGE Therapeutics
,
FDA
,
Zurzuvae
,
postpartum depression
,
major depressive disorder
,
zuranolone
Biogen looks at selling biosims unit to longtime ally Samsung Bioepis: reports
Fierce Pharma
Thu, 08/3/23 - 09:59 am
Tags:
Biogen
,
biosimilars
,
M&A
,
Samsung Bioepis
The real costs of the new Alzheimer’s drug, most of which will fall to taxpayers
Medical Marketing and Media
Wed, 08/2/23 - 10:43 pm
Tags:
Eisai
,
Biogen
,
Leqembi
,
Alzheimer's disease
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Motley Fool
Tue, 08/1/23 - 11:55 am
Tags:
Biogen
,
Reata Pharmaceuticals
,
M&A
After quitting FDA adcomm in protest of Aduhelm decision, Harvard's Aaron Kesselheim finds agency has an approval bias
Fierce Pharma
Mon, 07/31/23 - 10:07 am
Tags:
FDA
,
Biogen
,
Aduhelm
,
Alzheimer's disease
,
advisory committees
,
drug approvals
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
BioSpace
Mon, 07/31/23 - 10:05 am
Tags:
FDA
,
graft vs host disease
,
head and neck cancer
,
postpartum depression
,
major depressive disorder
,
Mesoblast
,
remestemcel-L
,
Biogen
,
SAGE Therapeutics
,
zuranolone
,
Galera Therapeutics
,
avasopasem manganese
Go or no go? Biogen and Astellas head towards key PDUFAs
EP Vantage
Sat, 07/29/23 - 10:45 pm
Tags:
FDA
,
Astellas
,
Zimura
,
Biogen
,
SAGE Therapeutics
,
zuranolone
,
major depressive disorder
,
postpartum depression
,
geographic atrophy
Biogen to acquire rare disease drugmaker Reata for $7.3B
BioPharma Dive
Fri, 07/28/23 - 11:50 am
Tags:
Biogen
,
Reata Pharmaceuticals
,
M&A
,
Friedreich's Ataxia
Sage Stock Drops Despite Promising Phase III Depression Data
BioSpace
Thu, 07/27/23 - 11:30 am
Tags:
SAGE Therapeutics
,
zuranolone
,
Biogen
,
depression
I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO
Motley Fool
Thu, 07/27/23 - 10:17 am
Tags:
Biogen
,
Alzheimer's disease
,
Pharma CEOs
,
Chris Viehbacher
Biogen to eliminate 1,000 jobs in further cost cuts
BioPharma Dive
Tue, 07/25/23 - 11:58 am
Tags:
Biogen
,
layoffs
,
R&D
After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version
Fierce Pharma
Thu, 07/20/23 - 10:09 am
Tags:
Eisai
,
Biogen
,
Leqembi
,
FDA
,
Alzheimer's disease
,
subcutaneous drug delivery
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Clinical Trials Arena
Wed, 07/19/23 - 10:27 am
Tags:
Eli Lilly
,
donanemab
,
Eisai
,
Biogen
,
Leqembi
,
Alzheimer's disease
Medicare’s Proposed Coverage for Alzheimer’s Scan Could Be Boon for Eisai/Biogen
BioSpace
Tue, 07/18/23 - 11:36 am
Tags:
CMS
,
Alzheimer's disease
,
Eisai
,
Biogen
,
PET scans
Why new Alzheimer’s drugs are in for a tepid launch
Medical Marketing and Media
Sun, 07/16/23 - 03:11 pm
Tags:
Alzheimer's disease
,
drug launches
,
Biogen
,
Eisai
,
Leqembi
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
Motley Fool
Thu, 07/13/23 - 10:16 am
Tags:
Biogen
,
Eisai
,
Leqembi
,
Alzheimer's disease
How will the price of Eisai and Biogen's Leqembi impact Medicare? Sen. Sanders wants to know
Fierce Pharma
Wed, 07/12/23 - 11:03 pm
Tags:
Eisai
,
Biogen
,
Leqembi
,
drug pricing
,
Medicare
,
Alzheimer's disease
Following in Biogen's wake, BrainStorm analyzes effect of ALS cell therapy on biomarker
Fierce Biotech
Fri, 07/7/23 - 08:40 am
Tags:
BrainStorm Cell Therapeutics
,
ALS
,
cell therapy
,
Biogen
,
NurOwn
Leqembi Wins Full FDA Approval as First Anti-Amyloid Antibody for Alzheimer’s
BioSpace
Thu, 07/6/23 - 10:08 pm
Tags:
Biogen
,
Eisai
,
Leqembi
,
FDA
,
Alzheimer's disease
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
Fri, 06/30/23 - 11:52 am
Tags:
FDA
,
Eisai
,
Biogen
,
Leqembi
,
Alzheimer's disease
,
SAGE Therapeutics
,
zuranolone
,
postpartum depression
,
major depressive disorder
,
Roche
,
Tecentriq
,
non-small cell lung cancer
,
CRISPR Therapeutics
,
Bluebird Bio
,
lovo-cel
,
exa-cel
,
BrainStorm Cell Therapeutics
,
NurOwn
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
An earthquake would most likely shake a: idea, building, breeze
*
Fill in the blank.